Novartis AG (NVSEF)
USD 114.59
(-0.0%)
USD 114.59
(-0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 34.18 Billion USD | -5.93% |
| 2022 | 36.34 Billion USD | -1.8% |
| 2021 | 37.01 Billion USD | 6.42% |
| 2020 | 34.77 Billion USD | 1.53% |
| 2019 | 34.25 Billion USD | -1.46% |
| 2018 | 34.75 Billion USD | 5.46% |
| 2017 | 32.96 Billion USD | 3.27% |
| 2016 | 31.91 Billion USD | -3.23% |
| 2015 | 32.98 Billion USD | -9.11% |
| 2014 | 36.28 Billion USD | -7.48% |
| 2013 | 39.22 Billion USD | 1.08% |
| 2012 | 38.8 Billion USD | -3.93% |
| 2011 | 40.39 Billion USD | 8.95% |
| 2010 | 37.07 Billion USD | 12.6% |
| 2009 | 32.92 Billion USD | 5.71% |
| 2008 | 31.14 Billion USD | 11.57% |
| 2007 | 27.91 Billion USD | 5.54% |
| 2006 | 26.45 Billion USD | 11.8% |
| 2005 | 23.65 Billion USD | 9.42% |
| 2004 | 21.62 Billion USD | 13.98% |
| 2003 | 18.97 Billion USD | 7.11% |
| 2002 | 17.71 Billion USD | 21.5% |
| 2001 | 14.57 Billion USD | -6.49% |
| 2000 | 15.58 Billion USD | 2.62% |
| 1999 | 15.18 Billion USD | -3.46% |
| 1998 | 15.73 Billion USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 9.93 Billion USD | 6.27% |
| 2024 Q1 | 8.43 Billion USD | -3.69% |
| 2024 Q2 | 9.35 Billion USD | 10.91% |
| 2023 Q3 | 8.97 Billion USD | -6.46% |
| 2023 Q4 | 8.75 Billion USD | -2.46% |
| 2023 FY | 34.18 Billion USD | -5.93% |
| 2023 Q1 | 9.27 Billion USD | 2.92% |
| 2023 Q2 | 9.59 Billion USD | 3.43% |
| 2022 Q3 | 9.03 Billion USD | -3.19% |
| 2022 FY | 36.34 Billion USD | -1.8% |
| 2022 Q4 | 9.01 Billion USD | -0.24% |
| 2022 Q1 | 8.95 Billion USD | -6.16% |
| 2022 Q2 | 9.33 Billion USD | 4.2% |
| 2021 Q4 | 9.54 Billion USD | 1.24% |
| 2021 Q2 | 9.38 Billion USD | 8.38% |
| 2021 FY | 37.01 Billion USD | 6.42% |
| 2021 Q1 | 8.65 Billion USD | -1.79% |
| 2021 Q3 | 9.42 Billion USD | 0.52% |
| 2020 Q1 | 8.98 Billion USD | 3.0% |
| 2020 Q3 | 8.78 Billion USD | 7.23% |
| 2020 Q2 | 8.19 Billion USD | -8.82% |
| 2020 Q4 | 8.81 Billion USD | 0.32% |
| 2020 FY | 34.77 Billion USD | 1.53% |
| 2019 Q4 | 8.72 Billion USD | 0.21% |
| 2019 Q1 | 8.2 Billion USD | -6.11% |
| 2019 Q3 | 8.7 Billion USD | 1.02% |
| 2019 Q2 | 8.61 Billion USD | 5.05% |
| 2019 FY | 34.25 Billion USD | -1.46% |
| 2018 Q4 | 8.73 Billion USD | 10.29% |
| 2018 FY | 34.75 Billion USD | 5.46% |
| 2018 Q2 | 8.97 Billion USD | 4.68% |
| 2018 Q1 | 8.57 Billion USD | -1.16% |
| 2018 Q3 | 7.92 Billion USD | -11.72% |
| 2017 Q2 | 8.23 Billion USD | 7.24% |
| 2017 Q1 | 7.68 Billion USD | -5.38% |
| 2017 Q3 | 8.36 Billion USD | 1.61% |
| 2017 Q4 | 8.67 Billion USD | 3.66% |
| 2017 FY | 32.96 Billion USD | 3.27% |
| 2016 Q4 | 8.11 Billion USD | 1.81% |
| 2016 FY | 31.91 Billion USD | -3.23% |
| 2016 Q1 | 7.59 Billion USD | -7.96% |
| 2016 Q3 | 7.97 Billion USD | -3.1% |
| 2016 Q2 | 8.22 Billion USD | 8.29% |
| 2015 Q2 | 8.4 Billion USD | 2.27% |
| 2015 FY | 32.98 Billion USD | -9.11% |
| 2015 Q4 | 8.25 Billion USD | 1.95% |
| 2015 Q3 | 8.09 Billion USD | -3.71% |
| 2015 Q1 | 8.22 Billion USD | -8.01% |
| 2014 Q4 | 8.93 Billion USD | 0.66% |
| 2014 Q1 | 9.51 Billion USD | -5.32% |
| 2014 FY | 36.28 Billion USD | -7.48% |
| 2014 Q3 | 8.87 Billion USD | -7.23% |
| 2014 Q2 | 9.57 Billion USD | 0.58% |
| 2013 Q3 | 9.64 Billion USD | -2.78% |
| 2013 Q2 | 9.92 Billion USD | 3.38% |
| 2013 FY | 39.22 Billion USD | 1.08% |
| 2013 Q4 | 10.05 Billion USD | 4.18% |
| 2013 Q1 | 9.6 Billion USD | -3.82% |
| 2012 Q1 | 9.42 Billion USD | -4.55% |
| 2012 Q2 | 9.93 Billion USD | 5.32% |
| 2012 Q3 | 9.46 Billion USD | -4.7% |
| 2012 FY | 38.8 Billion USD | -3.93% |
| 2012 Q4 | 9.98 Billion USD | 5.46% |
| 2011 FY | 40.39 Billion USD | 8.95% |
| 2011 Q1 | 9.76 Billion USD | -1.77% |
| 2011 Q2 | 10.5 Billion USD | 7.58% |
| 2011 Q4 | 9.87 Billion USD | -3.59% |
| 2011 Q3 | 10.24 Billion USD | -2.46% |
| 2010 Q1 | 9.09 Billion USD | -4.01% |
| 2010 FY | 37.07 Billion USD | 12.6% |
| 2010 Q4 | 9.94 Billion USD | 8.54% |
| 2010 Q3 | 9.15 Billion USD | 5.08% |
| 2010 Q2 | 8.71 Billion USD | -4.21% |
| 2009 Q3 | 8.18 Billion USD | 3.4% |
| 2009 Q4 | 9.47 Billion USD | 15.77% |
| 2009 Q2 | 7.91 Billion USD | 7.86% |
| 2009 Q1 | 7.34 Billion USD | -2.3% |
| 2009 FY | 32.92 Billion USD | 5.71% |
| 2008 Q2 | 7.79 Billion USD | 2.93% |
| 2008 Q4 | 7.51 Billion USD | -6.18% |
| 2008 Q3 | 8 Billion USD | 2.81% |
| 2008 FY | 31.14 Billion USD | 11.57% |
| 2008 Q1 | 7.56 Billion USD | 5.73% |
| 2007 Q4 | 7.15 Billion USD | 5.51% |
| 2007 Q2 | 6.9 Billion USD | -2.64% |
| 2007 Q1 | 7.09 Billion USD | 4.19% |
| 2007 FY | 27.91 Billion USD | 5.54% |
| 2007 Q3 | 6.78 Billion USD | -1.72% |
| 2006 Q3 | 6.8 Billion USD | 0.15% |
| 2006 FY | 26.45 Billion USD | 11.8% |
| 2006 Q4 | 6.8 Billion USD | 0.04% |
| 2006 Q2 | 6.79 Billion USD | 13.41% |
| 2006 Q1 | 5.98 Billion USD | -3.96% |
| 2005 FY | 23.65 Billion USD | 9.42% |
| 2005 Q1 | 5.48 Billion USD | -3.65% |
| 2005 Q2 | 5.89 Billion USD | 7.42% |
| 2005 Q3 | 6.03 Billion USD | 2.44% |
| 2005 Q4 | 6.23 Billion USD | 3.26% |
| 2004 FY | 21.62 Billion USD | 13.98% |
| 2004 Q2 | 5.37 Billion USD | 5.41% |
| 2004 Q3 | 5.44 Billion USD | 1.21% |
| 2004 Q4 | 5.69 Billion USD | 4.63% |
| 2004 Q1 | 5.1 Billion USD | -0.37% |
| 2003 Q1 | 4.35 Billion USD | -27.91% |
| 2003 Q3 | 4.71 Billion USD | -1.46% |
| 2003 Q4 | 5.12 Billion USD | 8.75% |
| 2003 FY | 18.97 Billion USD | 7.11% |
| 2003 Q2 | 4.78 Billion USD | 9.68% |
| 2002 Q4 | 6.04 Billion USD | 57.09% |
| 2002 Q3 | 3.84 Billion USD | -10.53% |
| 2002 Q2 | 4.3 Billion USD | -11.47% |
| 2002 Q1 | 4.85 Billion USD | -5.45% |
| 2002 FY | 17.71 Billion USD | 21.5% |
| 2001 Q1 | 4.44 Billion USD | -25.52% |
| 2001 FY | 14.57 Billion USD | -6.49% |
| 2001 Q4 | 5.13 Billion USD | -7.86% |
| 2001 Q3 | 5.57 Billion USD | 71.52% |
| 2001 Q2 | 3.25 Billion USD | -26.78% |
| 2000 Q2 | 4.32 Billion USD | -24.07% |
| 2000 Q3 | 4.88 Billion USD | 12.83% |
| 2000 Q4 | 5.96 Billion USD | 22.13% |
| 2000 Q1 | 5.69 Billion USD | 0.0% |
| 2000 FY | 15.58 Billion USD | 2.62% |
| 1999 FY | 15.18 Billion USD | -3.46% |
| 1998 FY | 15.73 Billion USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | 1.456% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | 0.364% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | -13.438% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -304144.905% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -4498.418% |